PETCT预测TKI疗效的研究进展.pptVIP

* Last updated: February 2011 * * Last updated: February 2011 * * * Last updated: February 2011 * * Last updated: February 2011 * Figure 2. A, waterfall plot of SUV change of target lesions after 2-day treatment of gefitinib (n ?20). , this patient was excluded from later assessment because gefitinib was discontinued at 6 days. B, correlation between SUV change (DSUV%) at 2 days and CT size change (DCTsize%) at 1 month of target lesions (n ?19). C, agreement between metabolic response at 2 days on EORTC recommendations and morphologic overall response at 1 month on RECIST 1.0 (n ?19). k ?0.566. EGFR mutation status is also shown. ND, not determined; NT, not tested; PR, partial response; SD, stable disease; PD, progressive disease; PMR, partial metabolic response; SMD, stable metabolic disease; PMD, progressive metabolic disease. * Figure 3. A, PFS of metabolic responders (DSUV% 25%) and nonresponders (DSUV% 25%) at 2 days. B, PFS of metabolic responders (DSUV%20%) and nonresponders (DSUV%20%) at 2 days. C, PFS of metabolic responders (DSUV%25%) and nonresponders (DSUV%25%) at 1 month. One patient did not have an FDG-PET scan at 1 month, without missing a CT scan. D, PFS of morphologic responders and nonresponders at 1 month. E, PFS according to a single PET activity at 2 days (SUV 7, black; SUV 7, gray). P values were obtained using the log-rank test. * * Last updated: February 2011 * * Last updated: February 2011 * On ROC analysis, the AUC for prediction of non-progressive disease by PET2 was 0.86 (95% CI, 0.62 to 1.1; P = 0.04), corresponding to a maximum specificity of 0.80 and sensitivity of 0.86 for non-progressive disease at a cut-off of 21.6% reduction in SUVmax (Figure 1) and a positive predictive value (PPV) of 0.86, a negative predictive value (NPV) of 0.80, an accuracy of 0.83 and a maximum Youden index of 0.65. The use of this SUVmax cut-off value correctly classified 11/12 patients (7 with true progressive disease (Figures 2 and 3); 4 with true non